We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics
ALDX

24 hedge funds and large institutions have $38M invested in Aldeyra Therapeutics in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

20% more funds holding

Funds holding: 20 → 24 (+4)

16% more capital invested

Capital invested by funds: $32.8M → $38M (+$5.13M)

3.45% more ownership

Funds ownership: 48.78% → 52.23% (+3.5%)

Holders
24
Holders Change
+4
Holders Change %
+20%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
7
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
PA
Perceptive Advisors
New York
+$4.87M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.45M
3
SFM
Sphera Funds Management
Israel
+$1.54M
4
SM
Sabby Management
Florida
+$925K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$771K

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$760K
2
PVI
Pura Vida Investments
New York
-$669K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$476K
4
KCM
Knoll Capital Management
Florida
-$60.3K
5
TRCT
Tower Research Capital (TRC)
New York
-$17.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$12.9M +$4.87M +945,000 +49%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$8.53M -$476K -92,500 -5%
AIC
3
AWM Investment Company
New York
$4.56M – – –
SFM
4
Sphera Funds Management
Israel
$3.34M +$1.54M +300,000 +81%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$2.38M +$2.45M +475,000 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.48M +$771K +149,754 +103%
BC
7
Boxer Capital
California
$1.46M – – –
SM
8
Sabby Management
Florida
$898K +$925K +179,627 New
KCM
9
Knoll Capital Management
Florida
$620K -$60.3K -11,704 -9%
Millennium Management
10
Millennium Management
New York
$517K +$17.4K +3,385 +3%
WMSA
11
Weiss Multi-Strategy Advisers
New York
$325K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$274K +$9.85K +1,912 +4%
HP
13
Hikari Power
Japan
$188K +$194K +37,662 New
BlackRock
14
BlackRock
New York
$175K +$181K +35,095 New
Renaissance Technologies
15
Renaissance Technologies
New York
$132K +$135K +26,300 New
Northern Trust
16
Northern Trust
Illinois
$75K +$3.48K +675 +5%
Bank of America
17
Bank of America
North Carolina
$40K +$10.3K +2,000 +33%
Deutsche Bank
18
Deutsche Bank
Germany
$39K +$41K +7,961 New
Morgan Stanley
19
Morgan Stanley
New York
$14K -$973 -189 -6%
UBS Group
20
UBS Group
Switzerland
$9K +$9.42K +1,829 New
JP Morgan Chase
21
JP Morgan Chase
New York
$6K +$5.66K +1,100 New
Manulife (Manufacturers Life Insurance)
22
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$5K – – –
TRCT
23
Tower Research Capital (TRC)
New York
$2K -$17.5K -3,400 -90%
AIM
24
Acrospire Investment Management
Illinois
$2K +$2.28K +442 New
BBA
25
Baker Bros. Advisors
New York
– -$760K -142,000 Closed
1
2

ALDX Hedge Fund Activity: Q1 2017 in Review

24 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2017, worth a combined $38M — up 16% from $32.8M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ALDX positions and 2 closed out — a net gain of 7 holders — while 7 added to existing stakes and 4 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $4.87M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $760K sold.

  • 24 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2017, up from 20 in Q4 2016.
  • Funds reported $38M of Aldeyra Therapeutics stock for Q1 2017, up 16% quarter-over-quarter.
  • 9 funds opened new Aldeyra Therapeutics positions in Q1 2017 and 2 closed out, a net change of +7 holders.
  • The largest Aldeyra Therapeutics buyer in Q1 2017 was Perceptive Advisors, an estimated $4.87M added.
  • The largest Aldeyra Therapeutics seller in Q1 2017 was Baker Bros. Advisors, an estimated $760K sold.

Based on aggregated 13F filings for Q1 2017.